https://www.selleckchem.com/products/mrtx1133.html
Moreover, when coexisting with t(11;14), patients with 1q21 gain showed a comparable survival to those without 1q21 gain. For patients treated with novel induction regimens followed by ASCT, 1q21 gain also conferred an inferior prognosis. Multivariate analysis further confirmed 1q21 gain could independently predict shorter PFS and OS. In conclusion, 1q21 gain is an adverse prognostic factor for MM patients received ASCT. In conclusion, 1q21 gain is an adverse prognostic factor for MM patients received ASCT. To describe the first Austra
Like
Comment
Share
